Canada Gears Up For Expected Rise In Biosimilar Filings
Efforts are under way in Canada to strengthen the regulator’s ability to evaluate the growing number of biosimilar filings, and to increase confidence in the biosimilar regulatory framework through targeted outreach and education activities.
You may also be interested in...
Canada Decides Against Suffix-Based Biologics Naming System
Following a consultation with stakeholders, the Canadian regulator says identification of biologics using their brand and non-proprietary names has emerged as the most preferred option as it is consistent with current practice.
WHO Still Planning Biosimilar Naming Guidance, Gives Update On Prequalification Pilot
Despite putting it on hold last year, the World Health Organization is keeping its idea of biosimilar naming guidance alive. And at a recent conference it updated delegates on the pilot project for prequalifying biosimilar versions of infliximab and trastuzumab.
Canada Wants Views On Three Options For Naming Of Biologic Drugs
In the absence of an international convention on the naming of biological medicines, the Canadian regulator is looking at various options before it decides on a formal approach to distinguish between biologic drugs that have the same non-proprietary name. It wants to adopt an approach that allows accurate identification, is compatible with existing drug information systems and databases, and is easy to implement.